| Consensus-based Statement 9.S8 | |
|---|---|
| Expert consensus | Level of consensus ++ |
| Blood component therapy is currently the standard therapy for haemostasis, either using labile (cellular components, FFP) or stable (lyophilised factor concentrates) blood products, and should be administered early to prevent dilutional coagulopathy occurring in addition to the already existing loss of blood. | |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.